HC Wainwright Has Bearish Estimate for CGTX Q1 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for shares of Cognition Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.12) for the quarter, down from their prior estimate of ($0.11). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS and FY2026 earnings at ($0.28) EPS.

Other research analysts have also issued reports about the stock. Brookline Capital Management raised shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. Chardan Capital cut their price objective on shares of Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Finally, B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Cognition Therapeutics currently has an average rating of “Buy” and an average price target of $7.50.

Cognition Therapeutics Stock Performance

Cognition Therapeutics stock opened at $0.44 on Wednesday. The stock has a market capitalization of $18.35 million, a price-to-earnings ratio of -0.46 and a beta of 1.03. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95. The stock’s 50 day moving average price is $0.57 and its two-hundred day moving average price is $0.55.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Thursday, March 20th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same period last year, the business earned ($0.27) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CGTX. SG Americas Securities LLC bought a new position in Cognition Therapeutics in the 4th quarter valued at about $26,000. Two Sigma Investments LP raised its stake in shares of Cognition Therapeutics by 372.2% in the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after purchasing an additional 42,321 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Cognition Therapeutics in the third quarter valued at approximately $27,000. Geode Capital Management LLC boosted its position in shares of Cognition Therapeutics by 8.9% during the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after buying an additional 28,705 shares during the last quarter. Finally, Voss Capital LP purchased a new position in shares of Cognition Therapeutics during the fourth quarter valued at approximately $351,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.